Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
09 mai 2023 16h01 HE
|
Olema Oncology
Initiation of first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line metastatic breast cancer planned for the second half of 2023Interim Phase 2 clinical results of...
Olema Oncology Announces Upcoming Poster Presentation at the 2023 ESMO Breast Cancer Annual Congress
08 mai 2023 07h06 HE
|
Olema Oncology
SAN FRANCISCO, May 08, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mai 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, May 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Participate in Canaccord Genuity 2023 Horizons in Oncology Virtual Conference
13 avr. 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, April 13, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 avr. 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, April 04, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update
09 mars 2023 16h00 HE
|
Olema Oncology
Significant progress made advancing lead program, OP-1250, with more than 170 patients treated to date Initiating first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 mars 2023 17h00 HE
|
Olema Oncology
SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
02 mars 2023 16h05 HE
|
Olema Oncology
SAN FRANCISCO, March 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Participate at Upcoming Investor Conferences
21 févr. 2023 16h30 HE
|
Olema Oncology
SAN FRANCISCO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 févr. 2023 18h00 HE
|
Olema Oncology
SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...